Last Posted: Jun 15, 2020
- Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants
Y Yu, et al, JAMA Network Open, June 12, 2020 - Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review.
Ninatti Gaia et al. Diagnostics (Basel, Switzerland) 2020 May 10(6) - MHC-I genotype and tumor mutational burden predict response to immunotherapy
AM Goodman et al, Genome Medicine, May 19, 2020 - The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
Crumbaker Megan et al. Cancers 2020 May 12(5) - Development and validation of a five-immune gene prognostic risk model in colon cancer.
Chen Haitao et al. BMC cancer 2020 May 20(1) 395 - Immune-related adverse events of checkpoint inhibitors
MR Casals et al, Nature Rev did Primers - Radiomics and deep learning in lung cancer.
Avanzo Michele et al. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2020 May - Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?
RB Corcoran et al, JAMA Oncology, May 7, 2020 - Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu Hui et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 14(1) 25-36 - Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.
Pallocca Matteo et al. Journal of translational medicine 2019 17(1) 131
.png)
No hay comentarios:
Publicar un comentario